Clinical Research Directory

Model Development and Application Based on Renal Pathology Images

This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, between January 1, 2019, and March 31, 2026. Deep learning and image analysis techniques will be employed to develop and validate models for the pathological diagnosis and classification of kidney diseases. The study will also assess model performance in evaluating disease activity and chronicity, as well as investigate the association between image-derived features and long-term renal outcomes. Diagnoses will be established by consensus among three senior renal pathologists, who will serve as the reference standard. A minimum of 8,000 eligible cases are planned for inclusion, which will be divided into training, validation, and independent test sets.

Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP

The goal of this clinical trial is to compare a new intravenous drug, Anruikefen, with a traditional oral medication, nalfurafine orally disintegrating tablets, in improving sleep quality in patients with chronic kidney disease-associated pruritus. Sleep quality will be primarily assessed using the Pittsburgh Sleep Quality Index (PSQI). The study will also evaluate the safety of Anruikefen. The main questions it aims to answer are: * Does Anruikefen injection improve sleep quality better than oral nalfurafine? * Does Anruikefen injection improve patients' quality of life more than oral nalfurafine? Researchers will compare Anruikefen with nalfurafine (an active control drug) to evaluate differences in their effects on sleep quality in patients with chronic kidney disease-associated pruritus. Participants will: * Receive either Anruikefen injection (0.3 μg/kg, three times per week) or nalfurafine hydrochloride orally disintegrating tablets (2.5 μg once daily). * Continue treatment for 4 weeks, followed by a 1-week safety follow-up. * Complete the Pittsburgh Sleep Quality Index and other quality-of-life questionnaires after one month.

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

Rutgers University Study of the Genetics of Kidney Disease

The goal of this observational study is to learn more about how genes impact the risk of kidney disease. Anyone 18 or older living in the US is eligible, and a diagnosis of kidney disease is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.